Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

1. Interventions for smoking cessation in people diagnosed with lung cancer. (PubMed)

Interventions for smoking cessation in people diagnosed with lung cancer. Lung cancer is one of the most common causes of death from cancer worldwide. Smoking induces and aggravates many health problems, including vascular diseases, respiratory illnesses and cancers. Tobacco smoking constitutes the most important risk factor for lung cancer. Most people with lung cancer are still active smokers at diagnosis or frequently relapse after smoking cessation. Quitting smoking is the most effective (...) way for smokers to reduce the risk of premature death and disability. People with lung cancer may benefit from stopping smoking. Whether smoking cessation interventions are effective for people with lung cancer and whether one method of quitting is more effective than any other has not been systematically reviewed.To determine the effectiveness of smoking cessation programmes for people with lung cancer.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (accessed via

2019 Cochrane

2. Brigatinib (Alunbrig) - for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)

Brigatinib (Alunbrig) - for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) Published 10 June 2019 1 SMC2147 brigatinib 30mg, 90mg and 180mg film-coated tablets (Alunbrig®) Takeda UK Ltd 10 May 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows (...) : ADVICE: following a full submission assessed under the end-of-life and ultra-orphan medicine process brigatinib (Alunbrig®) is accepted for use within NHSScotland. Indication under review: as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. Brigatinib was associated with an objective response rate of 56% in a single-arm, open- label, phase II study in patients with ALK

2019 Scottish Medicines Consortium

3. Durvalumab (Imfinzi) - for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC)

Durvalumab (Imfinzi) - for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) Published 10 June 2019 1 SMC2156 durvalumab 50mg/mL concentrate for solution for infusion (Imfinzi®) AstraZeneca 10 May 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission (...) considered under the ultra-orphan and end of life process durvalumab (Imfinzi®) is accepted for use within NHSScotland. Indication under review: as monotherapy for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 [programmed cell death ligand 1] on =1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy. Durvalumab, compared with placebo, improved progression-free survival and overall

2019 Scottish Medicines Consortium

4. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. (PubMed)

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a programmed death ligand 1 (PD-L1) tumour proportion score (TPS) of 50% or greater. We investigated overall survival after treatment (...) with pembrolizumab monotherapy in patients with a PD-L1 TPS of 1% or greater.This randomised, open-label, phase 3 study was done in 213 medical centres in 32 countries. Eligible patients were adults (≥18 years) with previously untreated locally advanced or metastatic non-small-cell lung cancer without a sensitising EGFR mutation or ALK translocation and with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, life expectancy 3 months or longer, and a PD-L1 TPS of 1% or greater

2019 Lancet

5. Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation

Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation Durvalumab for treating locally advanced Durvalumab for treating locally advanced unresectable non-small-cell lung cancer unresectable non-small-cell lung cancer after platinum-based chemor after platinum-based chemoradiation adiation T echnology appraisal guidance Published: 1 May 2019 www.nice.org.uk/guidance/ta578 © NICE 2019. All rights reserved. Subject to Notice of rights (...) . They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum- based

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

6. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database. (PubMed)

Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database. Data sets linking comprehensive genomic profiling (CGP) to clinical outcomes may accelerate precision medicine.To assess whether a database that combines EHR-derived clinical data with CGP can identify and extend associations in non-small cell lung cancer (NSCLC).Clinical data from EHRs were linked with CGP results for 28 998 patients (...) EHRs.Overall survival (OS), time receiving therapy, maximal therapy response (as documented by the treating physician in the EHR), and clinical benefit rate (fraction of patients with stable disease, partial response, or complete response) to therapy.Among 4064 patients with NSCLC (median age, 66.0 years; 51.9% female), 3183 (78.3%) had a history of smoking, 3153 (77.6%) had nonsquamous cancer, and 871 (21.4%) had an alteration in EGFR, ALK, or ROS1 (701 [17.2%] with EGFR, 128 [3.1%] with ALK, and 42 [1.0

2019 JAMA

7. Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib

Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib Brigatinib for treating ALK Brigatinib for treating ALK-positiv -positive e advanced non-small-cell lung cancer advanced non-small-cell lung cancer after crizotinib after crizotinib T echnology appraisal guidance Published: 20 March 2019 nice.org.uk/guidance/ta571 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our (...) unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

8. Alectinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

Alectinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Alectinib (nicht kleinzelliges Lungenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (neues Anwendungsgebiet) (Version 1.0; Status: 28 March 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding (...) . IQWiG Reports – Commission No. A17-67 Alectinib (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V 1 (new therapeutic indication) Extract of dossier assessment A17-67 Version 1.0 Alectinib (non-small cell lung cancer) 28 March 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Alectinib (non-small cell lung cancer) – Benefit assessment according to §35a

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

9. Alectinib (non-small-cell lung cancer) - Addendum to Commission A17-67

Alectinib (non-small-cell lung cancer) - Addendum to Commission A17-67 1 Translation of addendum A18-30 Alectinib (nicht kleinzelliges Lungenkarzinom) – Addendum zum Auftrag A17-67 (Version 1.0; Status: 1 June 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 1 June 2018 1.0 Commission: A18-30 Version: Status: IQWiG Reports – Commission No. A18-30 (...) Alectinib (non-small cell lung cancer) – Addendum to Commission A17-67 1 Addendum A18-30 Version 1.0 Alectinib – Addendum to Commission A17-67 1 June 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Alectinib (non-small cell lung cancer) – Addendum to Commission A17-67 Commissioning agency: Federal Joint Committee Commission awarded on: 8 May 2018 Internal Commission No.: A18-30 Address

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

10. Atezolizumab (non-small cell lung cancer) – Addendum to Commission A17-50

Atezolizumab (non-small cell lung cancer) – Addendum to Commission A17-50 1 Translation of addendum A18-09 Atezolizumab (nicht kleinzelliges Lungenkarzinom) – Addendum zum Auftrag A17-50 (Version 1.0; Status: 23 February 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 23 February 2018 1.0 Commission: A18-09 Version: Status: IQWiG Reports (...) – Commission No. A18-09 Atezolizumab (non-small cell lung cancer) – Addendum to Commission A17-50 1 Addendum A18-09 Version 1.0 Atezolizumab – Addendum to Commission A17-50 23 February 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Atezolizumab (non-small cell lung cancer) – Addendum to Commission A17-50 Commissioning agency: Federal Joint Committee Commission awarded on: 5 February 2018

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

11. Bevacizumab (Zirabev) - cancers of the colon, rectum, breast, lung, kidney and cervix

Bevacizumab (Zirabev) - cancers of the colon, rectum, breast, lung, kidney and cervix 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/886373/2018 EMEA/H/C/004697 Zirabev (bevacizumab) An overview of Zirabev and why (...) it is authorised in the EU What is Zirabev and what is it used for? Zirabev is a cancer medicine that is used to treat adults with the following cancers: • cancer of the colon (large bowel) or the rectum (the last section of the bowel), when it has spread to other parts of the body; • breast cancer that has spread to other parts of the body; • a lung cancer called non-small cell lung cancer when it is advanced or has spread or come back, and cannot be treated with surgery. Zirabev can be used unless the cancer

2019 European Medicines Agency - EPARs

12. Non-invasive positive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients. (PubMed)

Non-invasive positive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients. Pulmonary complications are often seen during the postoperative period following lung resection for patients with lung cancer. Some situations such as intubation, a long stay in the intensive care unit, the high cost of antibiotics and mortality may be avoided with the prevention of postoperative pulmonary complications. Non-invasive positive pressure ventilation (NIPPV (...) ) is widely used in hospitals, and is thought to reduce the number of pulmonary complications and mortality after this type of surgery. Therefore, a systematic review is needed to critically assess the benefits and harms of NIPPV for patients undergoing lung resection. This is an update of a Cochrane review first published in 2015.To assess the effectiveness and safety of NIPPV for preventing complications in patients following pulmonary resection for lung cancer.We searched the Cochrane Central Register

2019 Cochrane

13. Exercise training for advanced lung cancer. (PubMed)

Exercise training for advanced lung cancer. Patients with advanced lung cancer have a high symptom burden, which is often complicated by coexisting conditions. These issues, combined with the indirect effects of cancer treatment, can cumulatively lead patients to continued deconditioning and low exercise capacity. This is a concern as exercise capacity is considered a measure of whole body health, and is critical in a patient's ability to participate in life activities and tolerate difficult (...) treatments. There is evidence that exercise training improves exercise capacity and other outcomes, such as muscle force and health-related quality of life (HRQoL), in cancer survivors. However, the effectiveness of exercise training on these outcomes in people with advanced lung cancer is currently unclear.The primary aim of this review was to investigate the effects of exercise training on exercise capacity in adults with advanced lung cancer. Exercise capacity was defined as the six-minute walk

2019 Cochrane

14. Crizotinib (Alunbrig) - for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)

Crizotinib (Alunbrig) - for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization

2019 Health Canada - Drug and Health Product Register

15. Short-Term Readmissions After Open, Thoracoscopic, and Robotic Lobectomy for Lung Cancer Based on the Nationwide Readmissions Database

Short-Term Readmissions After Open, Thoracoscopic, and Robotic Lobectomy for Lung Cancer Based on the Nationwide Readmissions Database Readmission after surgery is an established surrogate indicator of quality of care. We aimed to compare short-term readmission rates and patient outcomes between open, video-assisted thoracoscopic (VATS), and robotic lobectomies in the Nationwide Readmissions Database (NRD).Adults who underwent open, VATS, or robotic lobectomy for lung cancer from 2010 to 2014 (...) were evaluated. Propensity-matched analysis was used to assess differences in readmission characteristics, GDP-adjusted cost, and mortality.Of the 129,539 lobectomies for lung cancer, 74,493 (57.5%) were open, 48,185 (37.2%) VATS, and 6861 (5.3%) robotic. Open surgery was associated with significantly higher readmission rate (10.5 vs 9.3%, p < 0.001), mortality (2 vs 1.2%, p < 0.001), index hospitalization cost [$21,846 (16,158-31,034) vs $20,779 (15,619-27,920), p < 0.001], and length of stay [6

2019 EvidenceUpdates

16. Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study

Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study The US guidelines recommend low-dose CT (LDCT) lung cancer screening for high-risk individuals. New solid nodules after baseline screening are common and have a high lung cancer probability. Currently, no evidence exists concerning the risk stratification of non-resolving new solid nodules at first LDCT screening after initial detection.In the Dutch-Belgian Randomized Lung Cancer Screening (NELSON) trial (...) nodules were resolving, leaving 356 (52%) participants with a non-resolving new solid nodule, of whom 25 (7%) were diagnosed with lung cancer. At first screening after initial detection, volume doubling time (VDT), volume, and VDT combined with a predefined ≥200 mm3 volume cut-off had high discrimination for lung cancer (VDT, area under the curve (AUC): 0.913; volume, AUC: 0.875; VDT and ≥200 mm3 combination, AUC: 0.939). Classifying a new solid nodule with either ≤590 days VDT or ≥200 mm3 volume

Full Text available with Trip Pro

2019 EvidenceUpdates

17. Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study

Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study Veliparib, a poly (ADP ribose) polymerase inhibitor, potentiated standard chemotherapy against small-cell lung cancer (SCLC) in preclinical studies. We evaluated the combination of veliparib with cisplatin and etoposide (CE; CE+V) doublet in untreated, extensive-stage SCLC (ES-SCLC).Patients with ES-SCLC, stratified by sex and serum

2019 EvidenceUpdates

18. Whole brain radiotherapy provides little benefit for lung cancer that has spread

Whole brain radiotherapy provides little benefit for lung cancer that has spread Whole brain radiotherapy provides little benefit for lung cancer that has spread Discover Portal Discover Portal Whole brain radiotherapy provides little benefit for lung cancer that has spread Published on 10 January 2017 doi: Radiotherapy to the whole brain makes little difference to people with the commonest type of lung cancer that has spread to the brain and cannot be operated on. This mainly UK-based trial (...) found no difference in overall survival and quality of life among people who had whole brain radiotherapy plus usual supportive care compared with people who received supportive care alone. This is the largest trial to assess the effect of this treatment in people with non-small cell lung cancer and multiple brain metastases (cancer deposits in the brain). Practice has been changing since early results of the trial were released. The final results reinforce the message that this treatment has little

2019 NIHR Dissemination Centre

19. Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer

Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer Discover Portal Discover Portal Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer Published on 28 February 2017 doi: Postoperative radiotherapy increases the risk of death by 18% for patients with non-small cell lung cancer that has been removed by surgery. Just (...) recurrence rates. Most of the trials are from over 30 years ago, so there is the possibility that newer radiotherapy techniques may be less harmful. Nevertheless, this review provides the best evidence to date that postoperative radiotherapy may not be appropriate as a routine treatment for non-small cell lung cancer. Share your views on the research. Why was this study needed? Lung cancer is the second most common cancer in the UK with 37,453 new cases registered in 2014. The majority of lung cancers

2019 NIHR Dissemination Centre

20. Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: nested case-control study within Lung Cancer Cohort Consortium. (PubMed)

Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: nested case-control study within Lung Cancer Cohort Consortium. To conduct a comprehensive analysis of prospectively measured circulating high sensitivity C reactive protein (hsCRP) concentration and risk of lung cancer overall, by smoking status (never, former, and current smokers), and histological sub-type.Nested case-control study.20 population based cohort studies in Asia, Europe, Australia (...) , and the United States.5299 patients with incident lung cancer, with individually incidence density matched controls.Circulating hsCRP concentrations in prediagnostic serum or plasma samples.Incident lung cancer diagnosis.A positive association between circulating hsCRP concentration and the risk of lung cancer for current (odds ratio associated with a doubling in hsCRP concentration 1.09, 95% confidence interval 1.05 to 1.13) and former smokers (1.09, 1.04 to 1.14) was observed, but not for never smokers (P

Full Text available with Trip Pro

2019 BMJ